Your Smart Views

CASSAVA SCIENCES, INC. (NASDAQ: SAVA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Cassava Sciences, Inc. Investors of Upcoming Deadline - Cassava Sciences (NASDAQ:SAVA)

From Benzinga

CASSAVA SCIENCES, INC. (NASDAQ: SAVA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Cassava Sciences, Inc. Investors of Upcoming Deadline - Cassava Sciences (NASDAQ:SAVA)

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Do you, or did you, own shares of Cassava Sciences, Inc. SAVA?

Did you purchase your shares between February 7, 2024 and November 24, 2024, inclusive?

Did you lose money in your investment in Cassava Sciences, Inc.?

Do you want to discuss your rights?

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Cassava Sciences, Inc. ("Cassava" or the "Company") SAVA investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

If you purchased or acquired Cassava securities, and/or would like to discuss your legal rights and options please visit Cassava Sciences, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

A lawsuit was filed in the United States District Court for the Western District of Texas on behalf of investors who purchased or acquired the securities of Cassava between February 7, 2024 and November 24, 2024, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

According to the lawsuit, Defendants made misrepresentations concerning the Company's leading drug candidate, simufilam. Cassava later released topline results for the first of its two ongoing Phase 3 studies indicating that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.

If you wish to serve as lead plaintiff for the Class, you must file papers by February 10, 2025. A lead plaintiff is a representative party acting on other class members' behalf in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco

Investor Relations Manager

Bernstein Liebhard LLP

https://www.bernlieb.com

(212) 951-2030

[email protected]

Market News and Data brought to you by Benzinga APIs

Previous articleNext article

POPULAR CATEGORY

corporate

8185

miscellaneous

10779

wellbeing

8214

fitness

10853